The Future of Weight-Loss Drugs: Challenges and Market Potential

Eli Lilly CEO David Ricks discusses the challenges of scaling production for weight-loss drugs, with the expectation that they will only reach 50% of eligible overweight and obese individuals due to healthcare system and financial barriers. Competing with Novo Nordisk, Lilly's new oral weight-loss pill Foundayo faces high market potential against cost constraints.

Eli Lilly CEO David Ricks highlighted the hurdles faced by the weight-loss drug market, pointing out that factors like healthcare infrastructure and economic constraints could limit distribution to 50% of overweight and obese patients who could benefit. This was discussed in detail at a recent conference.

Currently, only 10% of overweight or obese individuals are using GLP-1 injectable and oral medications. Statins are used by 40-50% of eligible patients, a scenario Ricks suggests may represent a ceiling for weight-loss drugs as well.

The launch of Lilly's oral drug Foundayo aims to compete with Novo Nordisk's Wegovy, but its success depends on tackling production scale challenges and price barriers, as prices range from $149 to $349 monthly, making them accessible predominantly for wealthier individuals.

(With inputs from agencies.)